

## FULL PAPER


An Efficient Stereoselective Total Synthesis of Bioactive (3*R*,5*R*)-1-(4-Hydroxyphenyl)-7-phenylheptane-3,5-diol via Asymmetric Aldol Reaction

by Perla Ramesh\*, Atla Raju, and Nitin W. Fadnavis

Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad-500007, India (phone: +91-40-27191631; fax: +91-40-27160512; e-mail: perlaramesh@yahoo.co.in)


An efficient stereoselective total synthesis of (3*R*,5*R*)-1-(4-hydroxyphenyl)-7-phenylheptane-3,5-diol (**1**) is reported based on the *Mukaiyama* aldol reaction. The total synthesis of compound **1** was accomplished with 30% overall yield in simple eight steps from commercially available *trans*-cinnamaldehyde.

**Introduction.** – Diarylheptanoids are an important class of biologically active natural products. They have been shown to display promising biological activities including antioxidant, anticancer, and anti-inflammatory activities [1–7]. One such diarylheptanoid is (3*R*,5*R*)-1-(4-hydroxyphenyl)-7-phenylheptane-3,5-diol (**1**, Fig. 1), isolated from *Alpinia officinarum* (Zingiberaceae), which exhibits anti-emetic activity [8–10]. Recently, Reddy *et al.* reported the first total synthesis of **1** using *Sharpless* kinetic resolution and an asymmetric epoxidation as the key steps from commercially available 4-hydroxybenzaldehyde [11]. This synthetic method suffers from a large number of synthetic steps and a low overall yield. We herein report the total synthesis of **1** through *Mukaiyama* aldol reaction in simple eight steps with 30% overall yield.

Fig. 1. Structure of the diarylheptanoid **1**


**Results and Discussion.** – The retrosynthetic plan of the target molecule **1** is illustrated in Scheme 1. Compound **1** could be obtained by *Grignard* reaction and acetonide deprotection followed by Pd/C reduction of primary alcohol **7**. The latter could be derived from **4** by a successive implementation of diastereoselective reduction and acetonide protection.  $\delta$ -Hydroxy- $\beta$ -keto ester **4** can be easily prepared via asymmetric *Mukaiyama* aldol reaction between *Chan's* diene **3** and *trans*-cinnamaldehyde **2**.

To begin the synthesis, the commercially available *trans*-cinnamaldehyde **2** was subjected to the stereoselective *Mukaiyama* aldol reaction with *Chan's* diene **3** in the presence of catalytic amounts of Ti(*i*PrO)<sub>4</sub>/(*S*)-BINOL complex (2 mol-%) to furnish aldol product **4** [12][13] in 94% yield with >97% ee as determined by chiral HPLC [14]. *anti*-Selective reduction of **4** was performed with




Me<sub>4</sub>NBH(AcO)<sub>3</sub> to give the desired *anti*-diol **5** exclusively, isolated in 80% yield (*syn/anti* 1:19) [15][16]. The diol was protected as acetonide using 2,2-dimethoxypropane (DMP) and a catalytic amount of PPTS. The relative configuration of acetonide *anti*-**6** was confirmed by <sup>13</sup>C-NMR according to *Rychnovsky's* method [17][18]. In the <sup>13</sup>C-NMR spectrum of **6**, the C-atoms of the acetonide Me groups were observed at 24.6 and 25.2 ppm and that of the quaternary C-atom at 100.6 ppm, confirming the presence of the *anti*-acetonide **6** [13] (Fig. 2).

Then, the protected *anti*-diol ester **6** was reduced to the corresponding primary alcohol by treatment with LiAlH<sub>4</sub> in dry THF at 0° for 30 min. The primary OH group of **7** was reacted with TsCl in the presence of Et<sub>3</sub>N and DMAP (cat.) in CH<sub>2</sub>Cl<sub>2</sub> to obtain crude compound **8**, which was

Fig. 2. Key <sup>13</sup>C-NMR data of compound **6**

Scheme 2. Synthesis of Compound 1



used in the next step without further purification. The crude **8** was subjected to the coupling reaction with the *Grignard* reagent 4-(benzyloxy)phenylmagnesium bromide to afford the desired product **9** [11] in 84% yield [19]. Finally the target molecule **1** was obtained from **9** by acetonide deprotection using TsOH in MeOH, followed by hydrogenation over Pd/C in 69% yield [11] (Scheme 2). The spectroscopic data of synthetic compound **1** were in agreement with those reported for the natural one [11].

In conclusion, an efficient stereoselective total synthesis of (3*R*,5*R*)-1-(4-hydroxyphenyl)-7-phenylheptane-3,5-diol (**1**) was accomplished *via* the *Mukaiyama* aldol reaction and an *anti* selective reduction as key steps. The present approach reduces the number of steps and increases the overall yield of compound **1** to 30%.

The authors thank CSIR and UGC, New Delhi for financial assistance.

### Experimental Part

**General.** All solvents and reagents were purified by standard techniques. Anal. TLC: precoated SiO<sub>2</sub> 60 F<sub>254</sub> (0.5 mm) glass plates; visualization of the spots on TLC plates was achieved either by exposure to I<sub>2</sub> vapor or UV light. Column chromatography (CC): silica gel (SiO<sub>2</sub>, 60–120, 100–200 mesh). Optical rotations: JASCO DIP-370 digital polarimeter. IR Spectra: Perkin–Elmer infrared spectrophotometer with NaCl optics;  $\tilde{\nu}$  in cm<sup>-1</sup>. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra: Varian Gemini 500 and Bruker Avance 300 instrument; in CDCl<sub>3</sub>;  $\delta$  in ppm rel. to Me<sub>4</sub>Si as internal standard, *J* in Hz. MS: Micro Mass VG-7070 H mass spectrometer for ESI and VG Auto spec M mass spectrometer for FAB-MS; in *m/z*.

**Ethyl (5*S*,6*E*)-5-Hydroxy-3-oxo-7-phenylhept-6-enoate (4)** [12]. A mixture of Ti(*i*PrO)<sub>4</sub> (430 mg, 1.51 mmol), (*S*)-BINOL (433 mg, 1.51 mmol), and LiCl (128 mg, 3.0 mmol) in dry THF (20 ml) was stirred at r.t. under inert atmosphere for 1 h. After cooling the mixture to –78°, the *trans*-cinnamaldehyde **2** (1 g, 7.57 mmol) was added dropwise, followed, after 30 min, by silyloxydiene **3** [20] (2.8 g, 15.15 mmol) in THF (10 ml). The resulting soln. was stirred at the same temp. for 2 h. After warming to r.t., the mixture was stirred overnight (12 h). After completion of the reaction as indicated by TLC, the reaction was quenched with a sat. aq. soln. of NaHCO<sub>3</sub> (5 ml) and extracted with Et<sub>2</sub>O. The combined extracts were washed with brine,

dried (MgSO<sub>4</sub>), and concentrated under reduced pressure to obtain crude silylated product. The crude silylated adduct was dissolved in MeOH (20 ml), pyridinium *p*-toluenesulfonate (10 mg) was added, and the mixture was stirred for 2 h at r.t. After completion of the reaction (monitored by TLC), the volatiles were removed *in vacuo*, and the crude product was purified by CC to obtain adduct **4** [12] (1.86 g, 94%) as pale yellow oil.  $[\alpha]_D^{25} = -14.1$  (*c* = 1.0, CHCl<sub>3</sub>). IR (neat): 3452, 2991, 1732, 1716, 1032, 976, 748. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): 7.38–7.23 (*m*, 5 H); 6.64 (*d*, *J* = 16.0, 1 H); 6.20 (*dd*, *J* = 16.0, 6.1, 1 H); 4.81–4.77 (*m*, 1 H); 4.20 (*q*, *J* = 14.3, 7.1, 2 H); 3.50 (*s*, 2 H); 2.87 (*d*, *J* = 6.1, 2 H); 2.84 (*br. d*, *J* = 3.3, 1 H); 1.28 (*t*, *J* = 7.1, 3 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 202.6; 166.8; 136.3; 130.6; 129.7; 128.5 (2 C); 127.7; 126.4 (2 C); 68.3; 61.5; 49.9; 49.5; 14.0. ESI-MS: 263 [*M* + H]<sup>+</sup>, 285 [*M* + Na]<sup>+</sup>.

**Ethyl {(4*S*,6*S*)-2,2-Dimethyl-6-[(*E*)-2-phenylethenyl]-1,3-dioxan-4-yl}acetate (6)** [13]. Me<sub>4</sub>NBH(AcO)<sub>3</sub> (1.506 g, 5.724 mmol) was added to a mixture of dry MeCN (5 ml) and glacial AcOH (5 ml). The resulting mixture was stirred at r.t. for 30 min. The mixture was cooled to –40° and a soln. of **4** (1.0 g, 3.816 mmol) in MeCN (2 ml) was added drop-wise. The mixture was stirred at the same temp. for 3 h. 1*N* Potassium sodium tartrate (5 ml) and Et<sub>2</sub>O (30 ml) were added to the mixture, followed by aq. sat. Na<sub>2</sub>CO<sub>3</sub> soln. (10 ml). The aq. phase was extracted with Et<sub>2</sub>O (4 × 10 ml). The combined org. phases were dried (MgSO<sub>4</sub>), and concentrated under vacuum. The residue was chromatographed over SiO<sub>2</sub> (2:1 hexane/AcOEt) to give **5** as a colorless oil (901 mg, 80% yield).

To a stirred soln. of **5** (901 mg, 3.41 mmol), in CH<sub>2</sub>Cl<sub>2</sub> (10 ml) was added dimethoxypropane (0.84 ml, 6.82 mmol) and PPTS (10 mg, 0.4 mmol). The mixture was stirred at r.t. for 4 h. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 ml) and washed with aq. sat. NaHCO<sub>3</sub>. The combined org. phases were dried (MgSO<sub>4</sub>), and the solvent was evaporated *in vacuo*. The crude product was purified by CC (10:1 hexane/AcOEt) to afford **6** as a colorless oil (933 mg, 90% yield).  $[\alpha]_D^{25} = +19.2$  (*c* = 1.0, CHCl<sub>3</sub>). IR (neat): 3040, 2921, 1734, 1582, 1494, 1378, 1312, 1199, 1024, 967, 747. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): 7.39–7.20 (*m*, 5 H); 6.56 (*d*, *J* = 16.0, 1 H); 6.23 (*dd*, *J* = 16.0, 6.4, 1 H); 4.49–4.60 (*m*, 1 H); 4.42–4.32 (*m*, 1 H); 4.15 (*m*, 2 H); 2.58 (*dd*, *J* = 15.4, 8.0, 1 H); 2.48 (*dd*, *J* = 15.4, 5.4, 1 H); 1.99–1.93 (*m*, 1 H); 1.83–1.77 (*m*, 1 H); 1.43 (*s*, 3 H); 1.41 (*s*, 3 H); 1.26 (*t*, *J* = 7.1, 3 H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): 170.7; 136.5; 130.5; 129.4; 128.4 (2 C); 127.6; 126.4 (2 C); 100.6; 67.5; 63.2; 60.4; 40.8; 37.2; 25.2; 24.6; 14.1. ESI-MS: 305 [*M* + H]<sup>+</sup>, 327 [*M* + Na]<sup>+</sup>.

**2-[(4*R*,6*S*)-2,2-Dimethyl-6-[(*E*)-2-phenylethenyl]-1,3-dioxan-4-yl]ethanol (7)**. To a stirred suspension of LiAlH<sub>4</sub> (62 mg, 1.64 mmol) in dry THF (20 ml) was added drop-wise a soln. of **6** (500 mg, 1.644 mmol) in dry THF (5 ml) at 0°. The mixture was allowed to warm to r.t. and stirred for 30 min. The reaction was quenched by drop-

wise addition of sat. aq. Na<sub>2</sub>SO<sub>4</sub> soln. (2 ml). The solid material was filtered through a *Celite* pad and washed thoroughly with hot AcOEt (4 × 20 ml). The combined org. layers were dried (MgSO<sub>4</sub>). The solvent was removed *in vacuo* and the crude residue was subjected to CC to obtain pure alcohol **7** (366 mg, 85%) as colorless oil.  $[\alpha]_D^{25} = -21.2$  ( $c = 1.2$ , CHCl<sub>3</sub>). IR (neat): 3442, 2991, 1021, 915, 712. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): 7.39–7.22 (*m*, 5 H); 6.57 (*d*,  $J = 16.0$ , 1 H); 6.23 (*dd*,  $J = 16.0$ , 6.4, 1 H); 4.57–4.52 (*m*, 1 H); 4.19–4.13 (*m*, 1 H); 3.82–3.76 (*m*, 2 H); 1.92–1.75 (*m*, 4 H); 1.45 (*s*, 3 H); 1.43 (*s*, 3 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 136.5; 130.5; 129.4; 128.4 (2C); 127.6; 126.4 (2C); 100.5; 67.7; 66.4; 60.8; 37.7 (2C); 25.4; 24.8. ESI-MS: 263 ( $[M + H]^+$ ).

(4*R*,6*S*)-4-[2-[4-(Benzyloxy)phenyl]ethyl]-2,2-dimethyl-6-[(*E*)-2-phenylethenyl]-1,3-dioxane (**9**) [11]. To a stirred soln. of alcohol **7** (300 mg, 1.14 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (10 ml) was added Et<sub>3</sub>N (0.8 ml, 3.43 mmol), TsCl (326 mg, 1.71 mmol), and cat. amounts of DMAP at 0°. After the mixture was stirred at 25° for 1 h, the reaction was quenched with H<sub>2</sub>O (5 ml), and the resultant mixture was then extracted with AcOEt (2 × 10 ml). The extracts were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and concentrated *in vacuo*. The residue was directly used for the next step without purification.

A flask charged with LiCl (87 mg, 2.05 mmol) was heated *in vacuo* and flushed with Ar. To the flask were added 4-benzyloxyphenyl magnesium bromide (1.55 ml, 1M in THF, 1.54 mmol), **8** (428 mg, 1.02 mmol), and CuI (59 mg, 0.3 mmol) sequentially. The mixture was stirred at r.t. for 2 h and diluted with sat. NH<sub>4</sub>Cl. The resulting mixture was extracted with AcOEt (4 × 5 ml). The combined extracts were dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. The residue was purified by CC (hexane) to afford **9** (370 mg, 84%).  $[\alpha]_D^{25} = +6.0$  ( $c = 1.0$ , CHCl<sub>3</sub>). IR (neat): 2922, 1622, 1457, 1248. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.98 (*d*,  $J = 8.1$ , 2 H); 7.51–7.49 (*m*, 4 H); 7.40–7.30 (*m*, 6 H); 7.11 (*d*,  $J = 8.1$ , 2 H); 6.89 (*dd*,  $J = 14.8$ , 7.0, 1 H); 6.28 (*d*,  $J = 14.8$ , 1 H); 5.29 (*s*, 2 H); 4.68–4.56 (*m*, 1 H); 3.73–3.65 (*m*, 1 H); 2.63–2.56 (*m*, 2 H); 1.73–1.49 (*m*, 4 H); 1.43 (*s*, 6 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 157.0; 141.8; 137.4; 134.7; 130.2; 129.9; 129.7; 128.9; 128.1; 128.0; 114.9; 96.6; 70.1; 68.9; 68.5; 39.8; 39.4; 31.6; 31.1. ESI-MS: 451 ( $[M + Na]^+$ ).

(3*R*,5*R*)-1-(4-Hydroxyphenyl)-7-phenylheptane-3,5-diol (**1**) [11]. To a stirred soln. of **9** (200 mg, 0.46 mmol) in MeOH (5 ml) was added TsOH (10 mg), and the mixture was stirred for 3 h at r.t. After completion of the reaction as indicated by TLC, the reaction was quenched with sat. aq. soln. of Na<sub>2</sub>CO<sub>3</sub> (1 ml), and the mixture was extracted with AcOEt (4 × 10 ml). The combined org. extracts were washed with a sat. soln. of NaCl, dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. The crude diol was dissolved in MeOH, a cat. amount of Pd/C was added, and the mixture was stirred for 2 h under H<sub>2</sub> (1 atm) at r.t. After filtration and concentration, the crude residue was purified by CC to afford pure title compound **1** (96 mg, 69%) as yellow oil.  $[\alpha]_D^{25} = +9.0$  ( $c = 1.0$ , CHCl<sub>3</sub>). IR (neat): 3440, 2925, 2854, 1512, 1245, 1092, 823. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.27–7.13 (*m*, 5 H); 6.94

(*d*,  $J = 8.1$ , 2 H); 6.70 (*d*,  $J = 8.0$ , 2 H); 4.01–3.89 (*m*, 2 H); 2.80–2.49 (*m*, 4 H); 1.90–1.67 (*m*, 4 H); 1.61 (*t*,  $J = 5.2$ , 2 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 154.0; 141.8; 133.4; 129.4 (2C); 128.4 (2C); 128.3 (2C); 125.9; 115.4 (2C); 69.0; 68.9; 42.4; 39.0; 38.9; 32.1; 31.1. ESI-MS: 323 ( $[M + Na]^+$ ).

## REFERENCES

- [1] K.-S. Chun, K.-K. Park, J. Lee, M. Kang, Y.-J. Surh, *Oncol. Res.* **2002**, *13*, 37.
- [2] J. Ishida, M. Kozuka, H. Tokuda, H. Nishino, S. Nagumo, K. H. Lee, M. Nagai, *Bioorg. Med. Chem.* **2002**, *10*, 3361.
- [3] P. N. Yadav, Z. Liu, M. M. Rafi, *J. Pharmacol. Exp. Ther.* **2003**, *305*, 925.
- [4] H. J. Kim, S. H. Yeom, M. K. Kim, J. G. Shim, I. N. Paek, M. W. Lee, *Arch. Pharmacol. Res.* **2005**, *28*, 177.
- [5] H. Mohamad, N. H. Lajis, F. Abas, A. M. Ali, M. A. Sukari, H. Kikuzaki, N. Nakatani, *J. Nat. Prod.* **2005**, *68*, 285.
- [6] K. Akiyama, H. Kikuzaki, T. Aoki, A. Okuda, N. H. Lajis, N. Nakatani, *J. Nat. Prod.* **2006**, *69*, 1637.
- [7] H. Matsuda, S. Ando, T. Kato, T. Morikawa, M. Yoshikawa, *Bioorg. Med. Chem.* **2006**, *14*, 138.
- [8] K. K. Lee, B. D. Bahler, G. A. Hofmann, M. R. Mattern, R. K. Johnson, D. G. I. Kingston, *J. Nat. Prod.* **1998**, *61*, 1407.
- [9] S. Uehara, I. Yasuda, K. Akiyama, H. Morita, K. Takeya, H. Itokawa, *Chem. Pharm. Bull.* **1987**, *35*, 3298.
- [10] D. Shin, K. Kinoshita, K. Koyama, K. Takahashi, *J. Nat. Prod.* **2002**, *65*, 1315.
- [11] P. R. Reddy, C. Sudhakar, J. N. Kumar, B. Das, *Helv. Chim. Acta* **2013**, *96*, 289.
- [12] A. Kamal, T. Krishnaji, G. B. R. Khanna, *Tetrahedron Lett.* **2006**, *47*, 8657.
- [13] G. Sabitha, V. Bhaskar, S. S. S. Reddy, J. S. Yadav, *Tetrahedron* **2008**, *64*, 10207.
- [14] Q. Xu, J. Yu, F. Han, J. Hu, W. Chen, L. Yang, *Tetrahedron: Asymmetry* **2010**, *21*, 156.
- [15] D. A. Evans, K. T. Chapman, E. M. Carreira, *J. Am. Chem. Soc.* **1988**, *110*, 3560.
- [16] D. A. Evans, K. T. Chapman, *Tetrahedron Lett.* **1986**, *27*, 5939.
- [17] S. D. Rychnovsky, D. J. Skalitzky, *Tetrahedron Lett.* **1990**, *31*, 945.
- [18] S. D. Rychnovsky, B. Rogers, G. Yang, *J. Org. Chem.* **1993**, *58*, 3511.
- [19] K. Nakata, C. Feng, T. Tojo, Y. Kobayashi, *Tetrahedron Lett.* **2014**, *55*, 5774.
- [20] P. Brownbridge, T. H. Chan, M. A. Brook, G. J. Kang, *Can. J. Chem.* **1983**, *61*, 688.

Received July 22, 2015

Accepted October 2, 2015